Hepatitis C Triple Therapy Trial Begins with CTS-1027

[Guest guest]

Hepatitis C Triple Therapy Trial Begins with CTS-1027

Conatus Pharmaceuticals is optimistic that their developmental drug, CTS-1027, will give people with Hepatitis C a greater chance for beating the virus. In a Phase II Hepatitis C trial for previous non-responders, CTS-1027 is being paired with pegylated interferon and ribavirin.

Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)

SAN DIEGO, Jan. 28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

"There is a significant unmet medical need in HCV patients who have not responded to pegylated interferon and ribavirin. These patients often progress to cirrhosis, a life-threatening condition. CTS-1027 has the potential to increase the effectiveness of the combination of pegylated interferon and ribavirin in this population," said Dr. J. Pockros, Head, Division of Gastroenterology and Director of the SC Liver Research Consortium and The Scripps Clinic in La Jolla, CA.

Continue reading this entire article:http://www.prnewswire.com/news-releases/conatus-pharmaceuticals-initiates-phase-ii-clinical-trial-in-combination-with-pegylated-interferon-and-ribavirin-for-the-treatment-of-hepatitis-c-virus-hcv-82965622.html

http://www.hepatitis-central.com/mt/archives/2010/02/hepatitis_c_tri_1.html